FrancophonIA/ELRC3.0 huggingface dataset:
English: Gastrointestinal disorders diarrhoea, vomiting, nausea jaundice, stomatitis, constipation, dyspepsia pseudomembranous colitis, abdominal pain
Maltese: Disturbi gastrointestinali dijarrea, rimettar, nawseja suffejra, stomatite, stitikezza, dispepsja kolite psewdomembranuża, uġigħ ta' żaqq
English: Citric acid monohydrate
Maltese: Edetate disodium (EDTA) Citric acid monohydrate
English: Groupings of relevant species according to piperacillin / tazobactam susceptibility COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Enterococcus faecalis Listeria monocytogenes Staphylococcus aureus, methicillin-susceptible£
Maltese: B'MOD KOMUNI Mikroorganiżmi aerobiċi Gram-pożittivi Enterococcus faecalis Listeria monocytogenes Staphylococcus aureus, suxxettibbli għal methicillin£
English: No pharmacokinetic interactions have been noted between piperacillin / tazobactam and vancomycin.
Maltese: Ma kienu osservati l-ebda interazzjonijiet farmakokinetiċi bejn piperacillin / tazobactam u vancomycin.
English: The susceptibility of streptococci is inferred from the penicillin susceptibility.
Maltese: Is-suxxettibbilità ta' streptococci hi inferita mis-suxxettibbilità ta' penicillin.
English: In the following table, adverse reactions are listed by system organ class and MedDRA-preferred term.
Maltese: Fit-tabella li ġejja, ir-reazzjonijiet avversi huma elenkati skont il-klassi tal-organi tas-sistema u skont itterminu ppreferut MedDRA.
English: The mean half-life for piperacillin and tazobactam were 32% and 55% longer, respectively, in the elderly compared with younger subjects.
Maltese: Il-medja tal-half-life għal piperacillin u tazobactam kienu 32% u 55% itwal, rispettivament, fl-anzjani meta mqabbla ma' persuni iżgħar.
English: Skin and subcutaneous tissue disorders rash, including maculopapular rash urticaria, pruritus erythema multiforme, dermatitis bullous, exanthema toxic epidermal necrolysis, Stevens-Johnson syndrome
Maltese: Disturbi fil-ġilda u fit-tessuti ta' taħt il-ġilda raxx, li jinkludi raxx makulopapulari urtikarja, ħakk eritema multiforme, dermatite bullosa, raxx fil-ġilda nekrolisi epidermali tossika, is-sindrome ta' Stevens-Johnson
English: The direct Coombs test may be positive.
Maltese: It-test dirett ta' Coombs jista' jkun pożittiv.
English: Possible side effects are listed according to the following categories: - common: affects 1 to 10 users in 100 - uncommon: affects 1 to 10 users in 1,000 - rare: affects 1 to 10 users in 10,000 - very rare: affects less than 1 user in 10,000
Maltese: L-effetti sekondarji possibbli huma elenkati skont il-kategoriji li ġejjin: - komuni: jaffettwaw minn 1 sa 10 utenti minn kull 100 - mhux komuni: jaffettwaw minn 1 sa 10 utenti minn kull 1,000 - rari: jaffettwaw minn 1 sa 10 utenti minn kull 10,000 - rari ħafna: jaffettwaw inqas minn utent 1 minn kull 10,000
English: beta-lactamase inhibitors; ATC code: J01C R05
Maltese: J01C R05
English: TAZOCIN 4 g / 0.5 g contains 11.16 mmol (256 mg) of sodium.
Maltese: TAZOCIN 4 g/0.5 g fih 11.16 mmol (256 mg) ta' sodium.
English: Tazocin 2 g / 0.25 g powder for solution for infusion Tazocin 4 g / 0.5 g powder for solution for infusion piperacillin / tazobactam
Maltese: Tazocin 2 g/0.25 g trab għal soluzzjoni għall-infużjoni Tazocin 4 g/0.5 g trab għal soluzzjoni għall-infużjoni Piperacillin / tazobactam
English: Volume of solvent* to be added to vial 2 g / 0.25 g (2 g piperacillin and 0.25 g tacobactam) 10 ml 4 g / 0.50 g (4 g piperacillin and 0.5 g tacobactam)
Maltese: Volum ta' solvent* li jrid jiżdied mal-kunjett 2 g / 0.25 g (2 g piperacillin u 0.25 g tazobactam) 10 ml 4 g / 0.5 g (4 g piperacillin u 0.5 g tazobactam)
English: Blood and lymphatic system disorders leukopenia, neutropenia, thrombocytopenia anaemia, haemolytic anaemia, purpura, epistaxis, bleeding time prolonged, eosinophilia agranulocytosis, pancytopenia, activated partial thromboplastin time prolonged, prothrombin time prolonged, Coombs direct test positive, thrombocythaemia
Maltese: Disturbi taddemm u tassistema limfatika lewkopenija, newtropenija, trombocitopenija anemija, anemija emolitika, purpura, tifriġ, ilħruġ ta' demm idum aktar, eosinofilija agranuloċitosi, panċitopenija, żieda fil-ħin parzjali ta' tromboplastin attivat, żieda filħin ta' protrombin, test dirett ta' Coombs b'riżultat pożittiv, tromboċitemija
English: 80 mg Piperacillin / 10 mg Tazobactam per kg body weight / every 6 hours
Maltese: 80 mg ta' Piperacillin / 10 mg ta' Tazobactam għal kull kg ta' piż talġisem/kull 6 sigħat
English: 0.9% (9 mg/ml) sodium chloride solution for injection
Maltese: 0.9% (9 mg/ml) soluzzjoni ta' sodium chloride għall-injezzjoni Glucose 5%
English: 4 g / 0.5 g (4 g piperacillin and 0.5 g tacobactam) 20 ml
Maltese: g (4 g piperacillin u 0.5 g tazobactam) 20 ml
English: Creatinine clearance (ml/min)
Maltese: Tneħħija tal-krejatinina (ml/min)
English: 100 mg Piperacillin / 12.5 mg Tazobactam per kg body weight / every 8 hours
Maltese: 100 mg ta' Piperacillin / 12.5 mg ta' Tazobactam għal kull kg ta' piż talġisem/kull 8 sigħat
English: For information related to the administration of piperacillin / tazobactam with aminoglycosides please refer to sections 6.2 and 6.6.
Maltese: Għal informazzjoni marbuta mal-għoti ta' piperacillin / tazobactam b'aminoglycosides, jekk jogħġbok irreferi għal sezzjonijiet 6.2 u 6.6.
English: INHERENTLY RESISTANT ORGANISMS Aerobic Gram-positive micro-organisms Corynebacterium jeikeium Aerobic Gram-negative micro-organisms Legionella species
Maltese: B'MOD INERENTI Mikroorganiżmi aerobiċi Gram-pożittivi Corynebacterium jeikeium
English: Tazobactam, a beta-lactam structurally related to penicillins, is an inhibitor of many beta-lactamases, which commonly cause resistance to penicillins and cephalosporinsbut it does not inhibit AmpC enzymes or metallo beta-lactamases.
Maltese: Tazobactam, beta-lactam strutturalment relatat mal-penicillins, hu inibitur qawwi ta' ħafna betalactamases, li komunement jikkawżaw reżistenza għal penicillins u cephalosporins, iżda ma jinibixxix enzimi AmpC jew metallo beta-lactamases.
English: Each vial of Tazocin 2 g / 0.25 g contains 5.58 mmol (128 mg) of sodium and Tazocin 4 g / 0.5 g contains 11.16 mmol (256 mg) of sodium.
Maltese: Kull kunjett ta' Tazocin 2 g/0.25 g fih 5.58 mmol (128 mg) ta' sodium u Tazocin 4 g/0.5 g fih 11.16 mmol (256 mg) ta' sodium.
English: History of acute severe allergic reaction to any other beta-lactam active substances (e.g. cephalosporin, monobactam or carbapenem).
Maltese: Storja medika ta' reazzjoni allerġika akuta severa għal kwalunkwe sustanzi attivi beta-lactam oħrajn (eż. cephalosporin, monobactam jew carbapenem).
English: Tazobactam is metabolised to a single metabolite that has been found to be microbiologically inactive.
Maltese: Tazobactam jiġi metabolizzat għal metabolit wieħed li nstab li hu mikrobijoloġikament inattiv.
English: Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 18% of the tazobactam dose removed as the tazobactam metabolite.
Maltese: Id-dijalisi peritoneali tneħħi madwar 6% u 21% tad-dożi ta' piperacillin u tazobactam, rispettivament, b'sa 18% tad-doża ta' tazobactam li titneħħa bħala lmetabolit ta' tazobactam.
English: Tazocin 2 g / 0.25 g is administered by intravenous infusion (over 30 minutes).
Maltese: Tazocin 2 g/0.25 g jingħata permezz ta' infużjoni ġol-vini (fuq perjodu ta' 30 minuta).
English: The susceptibility of staphylococci is inferred from the oxacillin susceptibility.
Maltese: Is-suxxettibbilità ta' streptococci hi inferita mis-suxxettibbilità ta' oxacillin.
English: In a population PK analysis, estimated clearance for 9 month-old to 12 year-old patients was comparable to adults, with a population mean (SE) value of 5.64 (0.34) ml/min/kg.
Maltese: F'analiżi farmakokinetika tal-popolazzjoni, l-istima tat-tneħħija għal pazjenti li kellhom minn 9 xhur sa 12-il sena kienet komparabbli ma' dik ta' persuni adulti, b'valur medju (SE) tal-popolazzjoni ta' 5.64 (0.34) ml/min/kg.
English: Tazocin is indicated for the treatment of the following infections in adults and children over 2 years of age (see sections 4.2 and 5.1):
Maltese: Tazocin hu indikat għall-kura tal-infezzjonijiet li ġejjin f'persuni adulti u tfal li għandhom iktar minn sentejn (ara sezzjonijiet 4.2 u 5.1):
English: Piperacillin / tazobactam is widely distributed in tissues and body fluids including intestinal mucosa, gallbladder, lung, bile, and bone.
Maltese: Piperacillin / tazobactam jiġi ddistribwit ħafna fit-tessut u fil-fluwidi tal-ġisem, li jinkludu l-mukuża intestinali, il-bużżieqa tal-marrara, il-pulmun, il-bila, u l-għadam.
English: Anaerobic Gram-negative micro-organisms Bacteroides fragilis group
Maltese: Mikroorganiżmi anerobiċi Gram-negattivi
English: TAZOCIN Diluent volume (ml)
Maltese: Tazocin volum tad-dilwent (ml)
English: Co-administration with aminoglycosides
Maltese: Aminoglycoside
English: Complicated urinary tract infections (including pyelonephritis) Complicated intra-abdominal infections
Maltese: Infezzjonijiet ikkumplikati tal-apparat urinarju (li jinkludu pijelonefrite)
English: Route of administration
Maltese: Mekkaniżmu tar-reżistenza
English: 70 ml Type I glass vial with a bromo-butyl rubber stopper and flip-off seal.
Maltese: Kunjett tal-ħġieġ ta' tip I, ta' 70 ml, b'tapp tal-lastku tal-bromo-butyl u siġill flip-off.
English: • Inactivation of the piperacillin component by those beta-lactamases that are not inhibited by tazobactam: beta-lactamases in the Molecular class B, C and D. In addition, tazobactam does not provide protection against extended-spectrum beta-lactamases (ESBLs) in the Molecular class A and D enzyme groups.
Maltese: Flimkien ma' dan, tazobactam ma jipprovdix protezzjoni kontra extended-spectrum beta-lactamases (ESBLs) fil-gruppi ta' enzimi ta' Klassi molekulari A u D.
English: Tazocin 4 g / 0.5 g is administered by intravenous infusion (over 30 minutes).
Maltese: Tazocin 4 g/0.5 g jingħata permezz ta' infużjoni ġol-vini (fuq perjodu ta' 30 minuta).
English: 2 g / 0.25 g (2 g piperacillin and 0.25 g tacobactam)
Maltese: 2 g / 0.25 g (2 g piperacillin u 0.25 g tazobactam) 10 ml 4 g /0.50
English: Uncommon side effects: thrush (abnormal) decrease in white blood cells (leukopenia, neutropenia) and platelets (thrombocytopenia) allergic reaction headache, sleeplessness low blood pressure, inflammation of the veins (felt as tenderness or redness in the affected area) jaundice (yellow staining of the skin or whites of the eyes), inflammation of the mucous lining of the mouth, constipation, indigestion, stomach upset increase of certain enzymes in the blood (alanine aminotransferase increased, aspartate aminotransferase increased) itching, nettle rash increase of muscle metabolism product in the blood (blood creatinine increased) fever, injection site reaction yeast infection (candidal superinfection)
Maltese: Effetti sekondarji mhux komuni: tbajja' bojod tnaqqis (anormali) fiċ-ċelluli tad-demm bojod (lewkopenija, newtropenija) u plejtlits (tromboċitopenija) reazzjoni allerġika uġigħ ta' ras, ma tkunx tista' torqod pressjoni tad-demm baxxa, infjammazzjoni tal-vini (li tinħass bħala sensittività jew ħmura fiż-żona affettwata) suffejra (tbajja' sofor fil-ġilda jew l-abjad tal-għajnejn), infjammazzjoni tal-kisja mukuża tal-ħalq, stitikezza, indiġestjoni, taqlib ta' stonku żieda ta' ċerti enzimi fid-demm (żieda ta' alanine aminotransferase, żieda ta' aspartate aminotransferase) ħakk, raxx bħal dak ikkawżat mill-ħurrieq żieda fid-demm ta' prodott tal-metaboliżmu fil-muskoli (żieda fil-krejatinina tad-demm) deni, reazzjoni fis-sit tal-injezzjoni infezzjoni fungali (superinfezzjoni candidali)
English: Vascular disorders hypotension, thrombophlebitis, phlebitis flushing
Maltese: Disturbi vaskulari pressjoni taddemm baxxa, tromboflebite, flebite fwawar
English: Immune system disorders hypersensitivity anaphylactic/ anaphylactoid reaction (including shock)
Maltese: Disturbi fissistema immuni sensittività eċċessiva reazzjoni anafilattika/ anafilattojdi (li tinkludi xokk)
English: Very rare side effects: severe decrease of granular white blood cells (agranulocytosis), severe decrease of red blood cells, white blood cells and platelets (pancytopenia) prolonged time for blood clot formation (prolonged partial thromboplastin time, prothrombin time prolonged), abnormal lab test (positive direct Coombs), increase of platelets (thrombocythaemia) decrease of potassium in the blood (hypokalaemia), decrease of blood sugar (glucose), decrease of the blood protein albumin, decrease of blood total protein detachment of the top layer of the skin all over the body (toxic epidermal necrolysis), serious bodywide allergic reaction with skin and mucous lining rashes and various skin eruptions (StevensJohnson Syndrome) blood urea nitrogen increased
Maltese: Effetti sekondarji rari ħafna: tnaqqis sever ta' ċelluli tad-demm bojod granulari (agranuloċitosi), tnaqqis sever ta' ċelluli taddemm ħomor, ċelluli tad-demm bojod u plejtlits (panċitopenija) żieda fit-tul ta' ħin li d-demm tiegħek idum biex jagħqad (żieda fil-ħin parzjali ta' tromboplastin, żieda fil-ħin ta' protrombin), riżultati anormali ta' testijiet anormali tal-laboratorju (Coombs dirett pożittiv), żieda fil-plejtlits (tromboċitemija) tnaqqis fil-livell tal-potassium fid-demm (ipokalemija), tnaqqis fil-livell ta' zokkor fid-demm (glucose), tnaqqis fl-albumina tal-proteini fid-demm, tnaqqis fil-proteini totali fid-demm is-saff tan-naħa ta' fuq tal-ġilda madwar il-ġisem kollu jinqala' (nekrolisi epidermali tossika), reazzjoni allerġika serja madwar il-ġisem kollu b'raxx tal-ġilda u tal-kisja mukuża tal-ġilda u diversi eruzzjonijieti tal-ġilda (Sindrome ta' Stevens-Johnson) żieda fl-urea nitrogen fid-demm
English: Instructions for use TAZOCIN will be given by intravenous infusion (a drip for 30 minutes).
Maltese: Istruzzjonijiet għall-użu TAZOCIN ser jingħata permezz ta' infużjoni ġo vina (dripp għal 30 minuta).
English: The mixing of beta-lactam antibiotics with aminoglycosides, in vitro, can result in substantial inactivation of the aminoglycoside.
Maltese: It-taħlit ta' antibijotiċi beta-lactam ma' aminoglycosides, in vitro, jista' jirriżulta f'inattivazzjoni sostanzjali tal-aminoglycoside.
English: No data from controlled clinical studies are available.
Maltese: L-ebda dejta minn studji kliniċi kkontrollati mhi disponibbli.
English: After reconstitution, chemical and physical in-use stability of diluted infusion solutions has been demonstrated for 24 hours at 25°C and for 48 hours when stored in a refrigerator at 2-8°C, when reconstituted using one of the compatible solvents for further dilution of the reconstituted solution at the suggested dilution volumes (see section 6.6).
Maltese: Wara r-rikostituzzjoni, l-istabbiltà kimika u fiżika waqt l-użu tas-soluzzjonijiet dilwiti tal-infużjoni, intweriet għal 24 siegħa f'temperatura ta' 25°C u għal 48 siegħa meta jinħażnu fi friġġ f'temperatura ta' 2-8°C, meta jiġu rikostitwiti bl-użu ta' wieħed mis-solventi kompatibbli għal dilwizzjoni addizzjonali tassoluzzjoni rikostitwita fil-volumi ssuġġeriti tad-dilwizzjoni (ara sezzjoni 6.6).
English: Excessive serum concentrations of either piperacillin or tazobactam may be reduced by haemodialysis (see section 4.4).
Maltese: Konċentrazzjonijiet eċċessivi fis-serum ta' piperacillin jew ta' tazobactam jistgħu jitnaqqsu permezz ta' emodijalisi (ara sezzjoni 4.4).
English: The two main mechanisms of resistance to piperacillin / tazobactam are:
Maltese: Iż-żewġ mekkaniżmi ewlenin ta' reżistenza għal piperacillin / tazobactam huma:
English: Each vial of Tazocin 2 g / 0.25 g contains 5.58 mmol (128 mg) of sodium.
Maltese: Kull kunjett ta' Tazocin 2 g/0.25 g fih 5.58 mmol (128 mg) ta' sodium.
English: Due to the in vitro inactivation of the aminoglycoside by beta-lactam antibiotics, Tazocin and the aminoglycoside are recommended for separate administration.
Maltese: Minħabba l-inattivazzjoni in vitro tal-aminoglycoside minn antibijotiċi beta-lactam, Tazocin u laminoglycoside huma rakkomandati għal għoti separat.
English: Other microorganisms
Maltese: ORGANIŻMI REŻISTENTI
English: For nosocomial pneumonia and bacterial infections in neutropenic patients, the recommended dose is 4 g piperacillin / 0.5 g tazobactam administered every 6 hours.
Maltese: Għal pnewmonja nosokomijali u infezzjonijiet batterjali f'pazjenti newtropeniċi, id-doża rakkomandata hi ta' 4 g ta' piperacillin / 0.5 g ta' tazobactam mogħtija kull 6 sigħat.
English: Mean tissue concentrations are generally 50 to 100% of those in plasma.
Maltese: Il-medja tal-konċentrazzjonijiet fit-tessut huma ġeneralment minn 50 sa 100% ta' dawk fil-plażma.
English: Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium.
Maltese: Meta piperacillin jintuża fl-istess ħin ma' vecuronium, kien implikat fit-titwil tal-imblokk newromuskolari ta' vecuronium.
English: Metabolism and nutrition disorders hypokalaemia, blood glucose decreased, blood albumin decreased, blood protein total decreased
Maltese: Disturbi filmetaboliżmu u n-nutrizzjoni ipokalemija, tnaqqis tal-glucose fid-demm, tnaqqis tal-albumina fiddemm, tnaqqis talproteini totali fiddemm
English: Protein binding of the tazobactam metabolite is negligible.
Maltese: Ittwaħħil mal-proteini tal-metabolit ta' tazobactam hu negliġibbli.
English: 0.9% sodium chloride or 5% glucose * The dose of aminoglycoside should be based on patient weight, status of infection (serious or life-threatening) and renal function (creatinine clearance).
Maltese: 0.9% sodium chloride jew 5% glucose * Id-doża ta' aminoglycoside għandha tiġi bbażata fuq il-piż tal-pazjent, l-istat tal-infezzjoni (serja jew ta' periklu għall-ħajja) u funzjoni tal-kliewi (tneħħija tal-krejatinina).
English: TAZOCIN should not be added to blood products or albumin hydrolysates.
Maltese: Tazocin m'għandux jiġi miżjud ma' prodotti tad-demm jew albumin hydrolysates.
English: Tazocin should not be added to blood products or albumin hydrolysates.
Maltese: TAZOCIN m'għandux jiġi miżjud ma' prodotti tad-demm jew albumin hydrolysates.
English: Before initiating therapy with Tazocin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, other beta-lactam agents (e.g. cephalosporin, monobactam or carbapenem) and other allergens.
Maltese: Qabel tinbeda t-terapija b'Tazocin, għandha ssir investigazzjoni bir-reqqa dwar reazzjonijiet ta' sensittività eċċessiva fil-passat għal penicillins, mediċini beta-lactam oħrajn (eż. cephalosporin, monobactam jew carbapenem) u allerġens oħrajn.
English: Therapy with Tazocin may result in the emergence of resistant organisms, which might cause superinfections.
Maltese: It-terapija b'Tazocin tista' tirriżulta fl-iżvilupp ta' organiżmi reżistenti, li jistgħu jikkawżaw superinfezzjonijiet.
English: Co-administration of TAZOCIN with aminoglycosides Due to the in vitro inactivation of the aminoglycoside by beta-lactam antibiotics, TAZOCIN and the aminoglycoside are recommended for separate administration.
Maltese: L-għoti flimkien ta' TAZOCIN ma' aminoglycosides Minħabba l-inattivazzjoni in vitro tal-aminoglycoside minn antibijotiċi beta-lactam, TAZOCIN u laminoglycoside huma rakkomandati għal għoti separat.
English: Piperacillin, tazobactam, and desethyl piperacillin are also secreted into the bile.
Maltese: Piperacillin, tazobactam, u desethyl piperacillin jnixxu wkoll fil-bila.
English: TAZOCIN is used in children aged 2-12 years to treat infections of the abdomen such as appendicitis, peritonitis (infection of the fluid and lining of the abdominal organs), and gallbladder (biliary) infections.
Maltese: TAZOCIN jintuża fit-tfal li għandhom minn sentejn sa 12-il sena għall-kura ta' infezzjonijiet fiż-żona tażżaqq bħal appendiċite, peritonite (infezzjoni tal- fluwidu u tal-kisja tal-organi addominali u infezzjonijiet tal-bużżieqa tal-marrara (biljari).
English: Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics.
Maltese: Seħħ ħruġ ta' demm f'xi pazjenti li rċivew antibijotiċi beta-lactam.
English: For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.
Maltese: Għall-kundizzjonijiet tal-ħażna tal-prodott mediċinali rikostitwit u dilwit, ara sezzjoni 6.3. 6.5
English: Hepatobiliary disorders alanine aminotransferase increased, aspartate aminotransferase increased hepatitis, blood bilirubin increased, blood alkaline phosphatase increased, gammaglutamyltransferase increased
Maltese: Disturbi fil-fwied u fil-marrara żieda f'alanine aminotransferase, żieda f'aspartate aminotransferase epatite, żieda talbilirubina fiddemm, żieda ta' alkaline phosphatase fiddemm, żieda f'gammaglutamyltransferase
English: Common side effects: diarrhoea, vomiting, nausea skin rashes
Maltese: Effetti sekondarji komuni: dijarrea, rimettar, nawseja raxx tal-ġilda
English: The reconstituted solutions may be further diluted to the desired volume (e.g. 50 ml to 150 ml) with one of the following compatible solvents:
Maltese: Is-soluzzjonijiet rikostitwiti jistgħu jiġu dilwiti b'mod addizzjonali għall-volum mixtieq (eż. 50 ml għal 150 ml) b'wieħed mis-solventi kompatibbli li ġejjin:
English: The increase in half-life is two-fold and four-fold for piperacillin and tazobactam, respectively, at creatinine clearance below 20 ml/min compared to patients with normal renal function.
Maltese: Iż-żieda fil-half-life hi bid-doppju u b'erba' darbiet aktar għal piperacillin u tazobactam, rispettivament, fit-tneħħija talkrejatinina taħt 20 ml/min meta mqabbla ma' pazjenti b'funzjoni normali tal-kliewi.
English: A number of chemical urine protein measurement methods may lead to false-positive results.
Maltese: Numru ta' metodi ta' kejl kimiku ta' proteina fl-awrina jistgħu jwasslu għal riżultati pożittivi foloz.
English: The most commonly reported adverse reactions (occurring in 1 to 10 patients in 100) are diarrhoea, vomiting, nausea and rash.
Maltese: L-iktar reazzjonijiet avversi rrappurtati b'mod komuni (li jseħħu f'minn 1 sa 10 pazjenti minn kull 100) huma dijarea, rimettar, nawseja u raxx.
English: Serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid [including shock]) reactions have been reported in patients receiving therapy with penicillins, including piperacillin / tazobactam.
Maltese: Reazzjonijiet serji u xi kultant fatali ta' sensittività eċċessiva (anafilattiċi/anafilattojdi [li jinkludu xokk]) kienu rrappurtati f'pazjenti li kienu qed jirċievu terapija bil-penicillins, li jinkludu piperacillin / tazobactam.
English: Tazocin and associated names (see Annex I) 2 g / 0.25 g powder for solution for infusion Tazocin and associated names (see Annex I) 4 g / 0.5 g powder for solution for infusion Piperacillin / tazobactam
Maltese: Tazocin u ismijiet assoċjati (ara Anness I) 2 g/0.25 g trab għal soluzzjoni għall-infużjoni Tazocin u ismijiet assoċjati (ara Anness I) 4 g/0.5 g trab għal soluzzjoni għall-infużjoni [Ara Anness I - Biex timtela mill-pajjiż partikolari]
English: Important information about some of the ingredients of TAZOCIN TAZOCIN 2 g / 0.25 g contains 5.58 mmol (128 mg) of sodium.
Maltese: Tagħrif importanti dwar xi wħud mis-sustanzi ta' TAZOCIN TAZOCIN 2 g/0.25 g fih 5.58 mmol (128 mg) ta' sodium.
English: Maximum recommended volume of sterile water for injection per dose is 50 ml.
Maltese: Il-volum massimu rakkomandat ta' ilma sterilizzat għal injezzjoni f'kull doża hu ta' 50 ml.
English: Pregnancy There are no or a limited amount of data from the use of Tazocin in pregnant women.
Maltese: Tqala M'hemmx dejta jew hemm dejta limitata dwar l-użu ta' Tazocin f'nisa tqal.
English: Tazobactam and its metabolite are eliminated primarily by renal excretion, with 80% of the administered dose appearing as unchanged substance and the remainder as the single metabolite.
Maltese: Tazobactam u l-metabolit tiegħu jitneħħew primarjament permezz ta' tneħħija mill-kliewi, bi 80% taddoża mogħtija li tidher bħala sustanza mhux mibdula u l-bqija bħala l-metabolit waħdu.
English: If bleeding manifestations occur, the antibiotic should be discontinued and appropriate therapy instituted.
Maltese: Jekk iseħħ ħruġ ta' demm, l-antibijotiku għandu jitwaqqaf u tinbeda terapija adattata.